Introduction
Herpes simplex virus type 1 (HSV-1)-based vectors have the capacity to deliver up to 150 kbp of foreign DNA to the nucleus of most proliferating and quiescent mammalian cells, making this family of vectors a very interesting and versatile tools for gene transfer and gene therapy. The uniqueness of HSV-1-based vectors stems from several properties of HSV-1, including (i) the very large capacity of the virus particle, (ii) the virus DNA will not integrate into host chromosomes, thus reducing the risk of insertional mutagenesis, (iii) the complexity of the virus genome, which contains some 40 genes that are not essential for virus replication, and can therefore be deleted without disturbing virus production in cultured cells and (iv) the capacity of HSV-1 to infect the nervous system, including the ability to trans-synaptically spread from neuron to neuron in both anterograde and retrograde directions, and the capacity to establish latent infections in the neurons.
Three different types of vectors can be derived from HSV-1, which attempt to exploit one or more of these properties ( Figure 1 ). (1) Recombinant oncolytic viruses are replication-competent HSV-1 vectors generally carrying attenuating mutations that restrict the spread and lytic viral replication to cancer cells, without causing major toxicity to the healthy tissues. (2) Disabled, replication-incompetent non-pathogenic recombinant HSV-1 vectors lack one or more essential replication genes, but retain many advantageous features of wild-type HSV-1, particularly the ability to express transgenes after having established latent infections in the central and peripheral neurons. (3) Amplicon vectors are defective, helper-dependent
In brief Progress
Amplicon infection induces a cascade of innate responses that can result in tissue-dependent restriction of transgene expression. Amplicon-mediated transgene expression is at least partially silenced by inherent antiviral responses. Novel cell type or cell cycle regulatory sequences that result in tissue-specific regulation of transgene expression. Recent improvements in transgene stability through the use of integrative strategies. Recent improvements in transgene stability through the use of non-integrative strategies. Transduction of progenitor cells using amplicon vectors.
Prospects
The engineering of the amplicon plasmid and the helper genome through the use of bacterial artificial chromosome technology is greatly facilitating the development of novel and better amplicon systems. Non-invasive imaging technologies will greatly stimulate the application of amplicon vectors to larger animal models and perhaps to human beings. vectors that carry no viral genes and take advantage of the large carrier capacity of the virus particle to deliver long transgenic sequences. Importantly, there is currently no other mammalian vector that equals the ability of amplicons to deliver up to 150 kbp of foreign DNA.
The genome of amplicon vectors derives from a plasmid, named the amplicon plasmid, which carries one packaging signal and one origin of DNA replication from HSV-1. As it carries no virus genes, this plasmid requires the presence of a helper virus genome that express the proteins necessary for its amplification and packaging into HSV-1 particles. 1 Over the last decade, technological improvements have enabled the production of large amounts of amplicon stocks which are, not or only, minimally contaminated with helper virus particles, and to use these vectors to deliver long genomic sequences to target cells. 1 These major breakthroughs have made it possible to study important aspects of the biological properties of amplicons in the absence of helper HSV-1. However, our understanding of amplicon biology remains fragmentary in many aspects. This review will focus on the recent advances in our understanding of amplicon biology and on the improvements in amplicon technology that have been published in the last two years.
Progress
Amplicon infection induces a cascade of innate responses that can result in tissue-dependent restriction of transgene expression One critical unresolved question is the understanding of the factors that induce silencing of helper-free amplicon-mediated transgene expression in many infected cell types. It is currently unclear why transgene expression mediated by helper-free amplicons is transient. Moreover, in the absence of systematic studies, we can only speculate about which virus proteins, if any, would be required to stabilize amplicon-mediated transgene expression. It is clear, however, that the strength and duration of gene expression is cell-type specific, ranging from strong expression in nerve or muscle cells that can last several days, to very weak or no expression in low-passage human fibroblasts, likely implying the involvement of cellular silencing factors. As UV-treated HSV-1, or HSV-1 mutants deficient in the expression of some immediate-early proteins, can trigger a strong antiviral response, one likely possibility is that amplicon-mediated transgene expression may be at least partially repressed by the establishment of an antiviral response in the target cells. In support of this hypothesis, it was shown that early activation of the Signal Transducer and Activator of Transcription 1 (STAT1) transcription factor, after systemic delivery of amplicon vectors into mice, suppresses transcription of the vectorencoded transgene in the liver. A similar experiment conducted in STAT1-knockout mice showed 10-fold higher transgene (luciferase) expression than in wildtype mice, and luciferase expression remained detectable during at least 80 days, whereas in wild-type mice luciferase expression became undetectable after 2 weeks post-infection. 2 Additional studies using fibroblasts derived from wild-type and STAT1-knockout mice, showed the significance of STAT1 signaling in transcriptional silencing of the amplicon-encoded transgene in vitro, indicating that type I interferons induced by systemic delivery of amplicons may initiate a cascade of immune responses that suppress transgene expression at the transcriptional level. 2 In a further study, antiviral responses were investigated after stereotactic amplicon administration into the mouse striatum. In the brain, induction of type I interferon was rather modest and transgene expression lasted over a year, despite inflammation and infiltration of immune cells around the injection sites. These findings indicate that the spectrum of host responses can differ significantly depending on the target organs and administration routes. 3 Amplicon infection of cultured human fetal foreskin fibroblasts 2 results in the induction of an interferon regulatory factor 3 (IRF3)-dependent antiviral response, characterized by upregulation of interferon stimulated genes (ISG) ISG54, ISG56, IRF7, toll-like receptor 3, and by low levels of b-interferon secretion. These responses also lead to the establishment of an antiviral state in the amplicon-infected cells, which become refractory to subsequent infection with vesicular stomatitis virus. 4 However, although amplicon-mediated transgene (green fluorescent protein (GFP)) expression is 5-20-fold lower in human fetal foreskin fibroblasts 2 cells than in human glioma cell lines or in mouse primary cardiomyocytes, as assessed both by scoring the number of GFP-expressing cells and by the median fluorescence intensity per cell, this seems not to be caused by the triggering of IRF3-dependent antiviral responses since siRNA-mediated downregulation of IRF3 before infection, although significantly reducing levels of ISG expression does not result in the enhancement of transgene expression from the amplicon genome.
4 Figure 1 The three types of HSV-1-based vectors. Recombinant vectors are herpes simplex virus type 1 (HSV-1) particles carrying an engineered HSV-1 genome. Recombinant vectors can be (1) attenuated, in which case they carry a mutation in a gene affecting virulence (white circle) and generally a reporter gene (in this case luciferase, white arrow) to facilitate following the spread of the virus, or (2) defective, in which case they carry a deletion in at least one gene encoding an essential function (grey circle). Defective vectors generally carry a transgene of interest (red arrow) and a reporter gene (in this case green fluorescent protein (GFP), green arrow) to identify the infected cells. Amplicon vectors (3) are HSV-1 particles carrying a head-to-tail concatemer of a DNA derived from the amplicon plasmid, instead of the virus genome. These plasmids also generally carry a reporter gene and a transgene of interest. In addition, they carry one HSV-1 origin of DNA replication (oriS) and one packaging signal ('a') to allow amplification and packaging of the plasmid into HSV-1 particles. Owing to the absence of genes encoding viral proteins, the amplicon plasmid can be amplified and packaged only in the presence of an HSV-1 helper genome.
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Amplicon-mediated transgene expression is at least partially silenced by inherent antiviral responses
In addition to the induction of IRF3 and STAT1-dependent antiviral responses, recent results suggest the occurrence of an inherent antiviral response that can block HSV-1 expression very early after infection in the absence of a viral immediate-early protein known as infected cell polypeptide 0 (ICP0). 5 This protein has an E3 ubiquitin ligase activity that induces proteasomic degradation of several cellular proteins, including the promyelocytyc leukemia (PML) protein, and the disruption of PML bodies (also known as ND10), which are involved in repression of gene expression. 5 In the absence of ICP0, PML and PML bodies are preserved, and this correlates with decreased ability to start a lytic infection in human fibroblasts. 5 As amplicons do not express ICP0 or any other immediate-early protein, this inherent antiviral response may also be partially responsible for the silencing observed in some cell types. Perhaps related to this hypothesis, it has been shown that the bacterial DNA sequences present in conventional amplicon vectors cause rapid transgene silencing by forming inactive chromatin in normal human fibroblasts. 6 Infection with amplicons devoid of bacterial sequences (minicircle amplicons) induced some 20-fold higher transgene expression, and quantitative analysis of levels of transgenic mRNA showed that the increase in transgene expression was at the transcription level. In addition, nude mice injected with minicircle amplicons exhibited 10-fold higher luciferase expression than mice injected with conventional amplicons. Furthermore, luciferase expression from conventional amplicons was undetectable 21 days after injection, whereas with the minicircle amplicons, expression was detectable up to at least 28 days post-infection. 6 In an earlier study, amplicons expressing GFP under the control of IE4/5 HSV-1 promoter and wild-type ICP0 driven by HCMV promoter expressed higher levels of GFP in human primary fibroblasts, cultured rat cardiomyocytes and rat neonatal cultured brain cells, than amplicons expressing no ICP0 or a mutated inactive form of ICP0, suggesting that ICP0 could play a significant role in suppressing a silencer activity in these cells. Furthermore, siRNA downregulation of Sp100 and Daxx, two regulatory proteins that localize to PML bodies, resulted in at least fivefold enhancement in the number of GFP-expressing human normal fibroblasts infected with standard amplicons. 4 As, as already quoted, one important role of ICP0 is to induce degradation of several ND10 constitutive proteins that are thought to contribute to silencing of gene expression, including PML and Sp100, these results lend further support to the hypothesis that an inherent antiviral mechanism is partially responsible for the silencing of ampliconmediated transgene expression in human fibroblasts. Lastly, the observation that the reduction of particleassociated ICP0 levels, that results from packaging the amplicon genome in the presence of the transcriptional regulator hexamethylene bisacetylamide, also results in reduced transgene expression, 7 provides further evidence for a role of ICP0 in suppressing silencing mechanisms that repress amplicon-mediated transgene expression.
Together, these data suggest that both the inherent and the induced innate antiviral responses can contribute to the silencing of helper-free amplicon-mediated transgene expression.
Novel cell type or cell cycle regulatory sequences that result in tissue-specific regulation of transgene expression
In addition to resolving the problem caused by gene silencing, most potential applications of amplicons into neurons or other cell types will require strict spatial and temporal control of transgene expression. Some recent studies have addressed this question by placing transgene expression under the control of cell type-specific genomic regulatory sequences or of cell cycle-specific regulatory sequences.
One study used amplicons carrying a LacZ transcription unit driven either by (i) the putative phosphateactivated glutaminase promoter (brain/kidney), (ii) the vesicular glutamate transporter 1 promoter (vesicular glutamate transporter 1, expressed mainly in the neocortex, the hippocampus and the cerebellum) or (iii) a 9 kbp fragment of the neocortex-specific glutamic acid decarboxylase 67 promoter. 8 When delivered into the post-rhinal cortex, the phosphate-activated glutaminase and vesicular glutamate transporter 1 promoters supported B90% glutamatergic neuron-specific expression, whereas the glutamic acid decarboxylase 67 promoter supported B90% GABAergic neuron expression. Long-term expression, at least 2 months after injection into the cortex, was observed using these promoters. 8 In a second study, an amplicon containing a 13.5 kbp genomic fragment encoding the gonadotropin-releasing hormone (GnRH) gene, together with its cognate promoter and regulatory elements, was administrated into the hypothalamic preoptic area of hypogonadal mice, which are deficient in GnRH production because of a deletion in the GnRH gene. After vector injection, an improvement in reproductive parameters of adult female homozygous hypogonadal mice was observed. GnRHexpressing neurons were detected in the preoptic area, and the pituitary and plasma gonadotropin levels, as well as ovarian and uterine weights, increased. In addition, a subset of injected hypogonadal mice showed cyclic estrous changes. These findings indicate that delivery of the genomic GnRH gene resulted in selective neuronal GnRH expression and regulated hypothalamic GnRH release. 9 In a very interesting study, an amplicon carrying a 135 kbp genomic insert, containing the entire 80 kbp Friedreich's ataxia (FRDA) human genomic locus, including long upstream and downstream regulatory sequences, was used to express frataxin, the protein encoded by this locus, in primary fibroblasts from patients with Friedreich's ataxia. 10 Expression of frataxin was observed by immune fluorescence. Functional complementation studies showed restoration of the wild-type cellular phenotype in response to oxidative stress in the Friedreich's ataxia-transduced cells. 10 The pro-apoptotic Fas ligand and Fas-associated protein with death domain coding genes were engineered into the cell cycle-regulated and transcriptionally targeted amplicon vector pC8-36. In this vector, gene expression from the minimal cyclin A promoter is
repressed by preventing the binding of a transactivating chimeric protein, Gal4-NF-YA, through selective interaction with the transcriptional repressor protein, CDF-1, which is absent in actively dividing cells. Fas ligand and Fas-associated protein with death domain expression mediated by this amplicon was shown to induce a higher percentage of cell death in proliferating cells than those observed in the G1-arrested cells. 11 The same group then reported the transcriptional activation of transgene expression in association with the onset of cellular proliferation using the mouse partial hepatectomy model. In this model, transcriptional regulation was rendered specific to human hepatocellular carcinoma cells by inserting the transactivating Gal4-NF-YA gene under the control of human hepatocellular carcinomaspecific regulatory sequences. 12 In a third study, the pC8-36 vector system was further improved by increasing the availability of binding sites for the CDF-1 repressor proteins in the regulatory sequences driving transgene expression. 13 These vectors confer better regulated and consistent transgene expression and have the potential as gene delivery vectors to target actively proliferating tumor cells. Together, these results show steady progress in the identification or construction of regulatory sequences conferring tissue-specific regulated expression of genes carried by the amplicon genome.
Recent improvements in transgene stability through the use of integrative strategies
Another major drawback of amplicon technology, that needs to be resolved to allow the application of these vectors in gene therapy settings, is related to the instability of the transgene cassette in the transduced cells. In addition to the above-mentioned difficulties related to the transcriptional control of transgene expression, long-term expression from standard amplicons cannot be maintained in dividing cells because of the dilution of the replication-incompetent standard vector genomes. In order to maintain and segregate the transgene cassettes in dividing cells, two distinct strategies are being developed. One of them attempts to confer long-term expression through the integration of the transgene cassette into host chromosomes. The second aims to confer long-term expression through the conversion of the amplicon genome into a replicationcompetent extrachromosomal element.
Hybrid amplicon systems. One strategy developed over several years is based on the use of hybrid amplicons carrying maintenance factors from other viruses. One of these models is the hybrid HSV-1/ adeno-associated virus (AAV) amplicon, which combines the large transgene capacity of HSV-1 particles with the potential of AAV to mediate the AAV1 site-specific genomic integration of transgene cassettes surrounded by the AAV inverted terminal repeats (ITR) in the presence of the AAV Rep protein. In the presence of Rep, these vectors have already been shown to support transgene expression for longer periods than standard amplicons. 14 More precisely, Rep-expressing hybrid amplicons supported ITR-bordered transgene retention and expression for over 2 weeks in cultured human U87 glioma cells and for at least 4 weeks in mouse hepatocytes after injection into mouse liver, while using standard amplicons or hybrid amplicons, but without Rep, expression disappeared after a few days.
14 A major problem associated with these hybrid amplicons is an inefficient production that seems to be because of the Rep protein interference with HSV-1 replication, thereby resulting in low packaging efficiency of the hybrid amplicons. In an attempt to overcome this problem, the HSV-1 origin of replication (OriS) was replaced by p5 sequences from the AAV genome, which can also act as origins of replication. This novel hybrid amplicon genome was more efficiently packaged into amplicon particles in the presence of Rep than amplicons carrying OriS.
14 An alternative approach consisted of designing a hybrid HSV/AAV vector that allowed conditional Rep expression. In this system Rep is not expressed in the packaging cells as it is separated from its promoter by a floxed intervening sequence, thus resulting in efficient levels of amplicon production, but will be transiently expressed in the transduced target cells, which have to express Cre recombinase to delete the intervening floxed sequences. 15 Although this system cannot be used in a Cre-negative environment, it opens interesting perspectives on how to resolve the problem arising from Rep expression during amplicon production.
In a recent study, hybrid HSV/AAV amplicons were used for the transfer of a 100 kbp genomic sequence containing the human lysosomal b-galactosidase gene. Transient expression and functional activity of b-galactosidase was detected in human b-galactosidase-deficient patient cells on infection with the BGAL vector in the presence of Rep expression. 16 Most of the Rep-positive clones possessed greater than normal b-galactosidase activity for up to 4 months of continuous growth and, furthermore, 33% of these clones exhibited AAV1 sitespecific integration of the ITR-flanked transgene.
In a series of studies to explore the feasibility of achieving stable gene replacement as potential treatment of ataxia-telangiectasia (AT), 17 an HSV/AAV hybrid amplicon carrying an expression cassette with the ATmutated (ATM) cDNA flanked by AAV ITRs was generated. In the presence of AAV Rep proteins, this vector mediated site-specific integration of the transgene cassette into the AAV1 site of chromosome 19 in human cells and in AtmÀ/À mice carrying that human locus. 18 The functional activity of the hybrid vector-derived ATM was confirmed in vivo by ATM auto-phosphorylation. This study confirmed the ability of HSV/AAV hybrid amplicon vectors to mediate functional targeted integration of the ATM cDNA into cultured AT cells and in AtmÀ/À mice in vivo.
Although these and earlier studies using HSV/AAV hybrid amplicons have clearly shown the feasibility of targeting integration of large transgene cassettes into the human AAV1 site, 14 it is noteworthy that multiple random integrations at other sites in the genome do occur. This very interesting system needs, therefore, to be further improved and, furthermore, genotoxic studies should be carried out to analyze whether Rep-directed transgene integration using these hybrid amplicons may be toxic or mutagenic for the target cells.
Transposons. A second more recent strategy to achieve amplicon integration into host chromosomes is the use of transposons. It has been shown that it is possible to induce integration of a transgenic cassette Herpes simplex virus type 1-based vectors AL Epstein flanked with repeated sequences of the Tcl family of transposons in the presence of a transposase or an integrase. Accordingly, a modified amplicon vector that uses the Tcl-like sleeping beauty (SB) transposon system to create an integrating amplicon vector platform has recently been constructed and tested. 19 In utero intraventricular application of this HSV/SB amplicon system led to extensive transgene expression within neuronal precursors without adverse consequences. A second study from the same group then showed that neuronal specificity of the HSV/SB amplicon transduction in utero was driven primarily by vector tropism and cell type composition. 20 These findings showed that in utero HSV/ SB amplicon gene transfer is primarily neuro specific, in part, because of the presence of multipotent target cell populations in the embryos that are efficiently infected by the vector and are supportive of SB-driven transposition. Whereas this novel and interesting vector system opens new potential applications, it should be stressed that, in contrast to the HSV-1/AAV hybrid system, integration of the transgenic cassette by the SB transposon is inherently not targeted and can take place at multiple random places. Therefore, genotoxic studies should be carried out to analyze the eventual toxicity or mutagenicity of the transposon-based transgene integration.
Recent improvements in transgene stability through the use of non-integrative strategies
Two strategies are currently being developed in order to transform the amplicon genome into a replicationcompetent extrachromosomal element. The first one uses the replication/segregation properties of scaffold/matrix attachment region (S/MAR) sequences, whereas the second uses technology on the basis of human artificial chromosomes (HACs). For a recent review on advances in episomal maintenance and expression of gene delivery vectors, see Lufino et al (2008) . 21 Scaffold/matrix attachment regions. A recent paper described the development of a high capacity episomal vector system exploiting human S/MARs sequences to provide vector maintenance and regulated gene expression through the delivery of a genomic DNA locus using amplicons. 22 This system was used to deliver and maintain a 135 kbp genomic DNA insert carrying the human low-density lipoprotein receptor (LDLR) genomic DNA locus at high efficiency in CHO clonal cells not expressing this receptor (ldlrÀ/À a7 cells). Long-term studies on CHO ldlrÀ/À a7 clonal cell lines carrying the S/MAR-LDLR amplicons showed episomal retention of one to four vector copies per cell, as estimated by Southern blots, and episomal stability of the vectors for more than 100 cell generations without selection. Expression studies of these cells showed restored LDLR function to physiological levels. This vector thus seems to simultaneously overcome the major problems of vector loss and unregulated transgene expression.
Human artificial chromosomes. An alternative approach to confer stability on episomal amplicons is to convert the amplicon genomes into HACs. HACs are linear or circular DNA molecules that contain human alphoid centromeric DNA sequences carrying repeated centromeric protein B binding motifs, which can confer segregation and retention to transduced DNA during the division of human cells. Traditional methods to deliver HACs involve laborious procedures with low effectiveness that usually results in HACs shearing and degradation. By introducing alphoid sequences of different lengths into an amplicon plasmid, Wade-Martins and coworkers 23 recently developed a series of HAC amplicon vectors that were used to transduce different human cell lines, including glioma, lung fibroblasts and kidney HEK 293T human cells, with an efficacy much higher than transfection-based methods. In fibrosarcoma cells, an HAC amplicon expressing hypoxanthine-guanine phosphorybosyltransferase (HPRT) successfully complemented the HPRT deficiency. It was also shown that the length of expression of the HAC was cell type dependent. Although in HEK 293T cells and in primary fibroblasts HACs were rapidly lost, in selected fibrosarcoma and glioma cells HACs were stable for more than 3 months. 23 Although many improvements to this system are certainly required, this study describes a very significant advance in amplicon technology.
Transduction of progenitor cells using amplicon vectors
The ability to achieve both stable transgene transduction and controlled expression, either by targeted integration or as an episomal element, is particularly critical given that amplicons can efficiently infect stem cells, thereby opening the way to create transgenic animals or to treat human diseases through infection of progenitor cells. Earlier studies had shown that amplicons expressing FGF-2 efficiently promoted neuron generation on delivery into mouse embryonic stem cells. 24 In a very interesting recent study, Lam and coworkers 25 used amplicon vectors to deliver GFP to human bonemarrow-derived mesenchymal stem cells (BM-hMSCs), non-hematopoietic stem cells that have the potential to differentiate into adipocytes, osteocytes and chondrocytes. As these cells can migrate to sites of injury, where they expand rapidly, BM-hMSCs can be exploited as gene transfer vehicles to deliver therapeutic genes. The authors observed that BM-hMSCs could be transduced with high efficiency, as B40% of GFP-positive cells were detected by flow cytometry in BM-hMSCs infected with amplicons at a multiplicity of infection of 1.0. Furthermore, infection with helper-free amplicons did not alter the intrinsic properties of these cells, including morphology, proliferation and chromosomal stability. Most important, amplicon infection did not alter the pluripotent differentiation potential and the tumor tropism of BM-hMSCs, 25 nor integrate into cellular chromosomes, therefore avoiding any genotoxic effect. Although the efficiency of migration of BM-hMSCs to the sites of injury has been reported to be low, this study illustrates a potentially very useful application of HSV-1-based amplicon vectors.
Prospects
A large number of in vitro and in vivo studies using helper-free amplicons that cannot be described in this short review, have shown the outstanding potential of these vectors for gene therapy of neurological diseases, for the treatment of brain and other malignancies, 27 for fundamental studies of neurobiological 28 or virological 29 interest, and as genetic vector vaccines against pathogens. 30 Despite encouraging results, translation to large animal models is challenging and concern remains about clinical application, except perhaps for cancer treatment. Reasons for this include our current inability to produce large amounts of purified high-titer helper-free amplicons and the limited information we possess regarding the biological properties of these vectors, including the control of transgene expression, inflammatory and immune responses raised by amplicon infection, and the possibility that these vectors could find resident HSV-1 genomes that, acting as natural helpers, could disseminate the inoculated amplicons outside the targeted tissues.
The engineering of the amplicon plasmid and the helper genome through the use of bacterial artificial chromosome technology is greatly facilitating the development of novel and better amplicon systems As described in this review, outstanding advances in several areas of amplicon biology are now being achieved. We do not doubt that progress will continue and accelerate in the future. In particular, our understanding of the inherent and induced innate responses, elicited by amplicon infection that are partially responsible for silencing transgene expression, will benefit from further studies using helper-free amplicons, defective recombinant HSV-1 vectors or wild-type HSV-1. This may suggest ways to prevent transgene silencing, for example, through the construction of amplicons rationally foresaw to be devoid of bacterial sequences, or carrying structural proteins that are able to counteract silencing mechanisms.
The recent application of BAC technology to engineer both the helper backbone and the vector genome, through homologous or site-specific recombination in bacteria, is facilitating the construction and exploration of novel amplicon systems endowed with increased ability to generate high-titer stocks, to be more efficiently purified and to have the protein and DNA composition less prone to the induction of deleterious host responses.
Non-invasive imaging technology will greatly stimulate application of amplicon vectors to larger animal models and perhaps to human beings At the same time, the application of newly developed molecular imaging technology, including positron emission tomography and in vivo bioluminescence imaging, to amplicon vectors in experimental animal models has recently allowed the non-invasive and quantitative imaging of transgene expression. This may serve both to non-invasively monitor the expression dynamics of any gene of interest both for research and for therapeutic applications, 31 and to localize and assess the biodistribution of the vector or of the reporter transgene in the inoculated organism. 32, 33 The combination of these novel technologies, together with the acquisition of further knowledge of the biology of amplicon vectors, and of its parent HSV-1, will certainly give a tremendous impel to the application of these vectors in novel experimental settings. HSV-1 amplicons have not yet been used in clinical trials or non-human primate studies. Perhaps the translation of this very versatile and powerful vector system to the clinic is not that far.
